Beijing SL Pharmaceutical (002038) Fundamentals 2026 — Revenue Analysis | SniperIQ
Beijing SL Pharmaceutical (002038) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥5.7B, trading at ¥5.55 on the SHZ. This SniperIQ fundamentals page covers Beijing SL Pharmaceutical's valuation, profitability (net margin -81.0%), revenue (¥624M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing SL Pharmaceutical's market cap?
Beijing SL Pharmaceutical (002038) has a market capitalization of approximately ¥5.7B, trading at ¥5.55 on the SHZ. Market cap moves with the live share price.
What is Beijing SL Pharmaceutical's P/E ratio?
Beijing SL Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing SL Pharmaceutical?
Beijing SL Pharmaceutical runs a net profit margin of -81.0%, a gross margin of 57.1%, and an operating margin of -115.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing SL Pharmaceutical generate?
Beijing SL Pharmaceutical reported revenue of ¥624M for fiscal year 2025, with net income of -¥347M and earnings per share (EPS) of -0.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing SL Pharmaceutical pay a dividend?
Beijing SL Pharmaceutical offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Beijing SL Pharmaceutical financially healthy?
Beijing SL Pharmaceutical carries a debt-to-equity ratio of 0.00x and a current ratio of 3.38x, with a market beta of -0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing SL Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing SL Pharmaceutical (002038) the key facts are: market cap ¥5.7B, revenue ¥624M, 52-week range 4.81-9.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing SL Pharmaceutical's full fundamentals live
Get Beijing SL Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.